BAYLOR COLLEGE OF MEDICINE will collaborate with Biocept Inc. to develop minimally invasive blood-based tests using Biocept's circulating tumor cell and circulating tumor DNA molecular diagnostic assay platforms to detect mutations in the estrogen receptor gene ESR1.
FDA approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these treatments. “Today’s approval is a first-of-its-kind therapy that can potentially save lives following overdose or life-threatening toxicity from these chemotherapy... […]
THE GUSTAVE ROUSSY Institute of Oncology is looking to recruit young doctors, pharmacists and engineers in France, Europe and the rest of the world, offering three-year research contracts to work with the institute's researchers toward the presentation of a doctoral thesis in sciences.
TERRILL JORDAN was named president and CEO of Regional Cancer Care Associates, effective Jan. 1, 2016.
DANIEL SIMON was named president of University Hospitals Case Medical Center, effective Jan. 1, 2016.
FDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, who have progressed on or are intolerant to crizotinib.
CARLOS RODRIGUEZ-GALINDO joined St. Jude Children's Research Hospital to head the International Outreach Program.
The American Society for Clinical Oncology and the American Cancer Society published a joint guideline for primary care physicians on managing the long-term care of breast cancer survivors, recommending regular surveillance for recurrence, but not performing laboratory or imaging tests in patients not displaying symptoms.
Eli Lilly and Company and Merck announced an immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase 4 and 6 inhibitor, and Merck’s Keytruda (pembrolizumab) in a phase I study across multiple tumor types. Based on the trial’s results, the collaboration has the potential to progress to phase II trials in patients who have... […]
Academic cancer centers have a major and unique role to play in enhancing cancer research, clinical care and education. This role will increase in value as our understanding of the complexity of cancer grows and is applied to care of patients.
